Abstract 1258: Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor

Authors: Barbara Brandhuber, Karin Ku, Maria J. Lallena, Carmen Baquero, Regina Choy, Kevin Ebata, Sophie Shu Lin, Lihua Jiang, Yanxin Liu, Xiangling Chen, Liguang Lou

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-1258

Source: Full article